Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...
WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), approximately one in eight men will be diagnosed with prostate cancer in ...
GlobalData on MSN
J&J reports positive data for Erda-iDRS in bladder cancer
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced the resubmission of its sBLA to the FDA for ANKTIVA in ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results